Rotavirus Vaccines Market Transforming Immunization Strategies

Revenue, 2025

USD 5.25 Billion

Forecast, 2035

USD 13.79 Billion

CAGR, 2026-2035

10.14%

Report Coverage

Global

Rotavirus Vaccines Market Size, Dynamics with Forecast and Key Players

The global rotavirus vaccines market size was estimated at USD 5.25 billion in 2025 and is predicted to increase from USD 5.78 billion in 2026 to approximately USD 13.79 billion by 2035, expanding at a CAGR of 10.14% from 2026 to 2035.

The growing rotavirus infections globally are increasing the demand for their vaccines, where the growing adoption of AI technologies is accelerating their production. The growing population, health awareness, and robust healthcare are also increasing their use to control outbreaks, where companies are also developing and investing in advanced rotavirus vaccines, promoting the market growth.

Key Takeaways

• Rotavirus vaccines industry poised to reach USD 5.78 billion by 2026.
• Forecasted to grow to USD 13.79 billion by 2035.
• Expected to maintain a CAGR of 10.14% from 2026 to 2035.
• Asia-Pacific held the major revenue share of approximately 35% in the global rotavirus vaccines market in 2025.
• MEA is expected to grow at the fastest CAGR of approximately 17% during the forecast period.
• By vaccine type, the pentavalent rotavirus vaccines segment held an approximate 48% share in the market in 2025.
• By vaccine type, the next-generation/broad-spectrum rotavirus vaccines segment is expected to grow at the fastest CAGR of approximately 14% during the forecast period.
• By route of administration type, the oral rotavirus vaccines segment held an approximate 95% share in the market in 2025.
• By route of administration type, the injectable (emerging formulation candidates) segment is expected to grow at the fastest CAGR of approximately 16% during the forecast period.
• By immunization program type, the government national immunization programs segment held an approximate 70% share in the market in 2025.
• By immunization program type, the NGO/public health initiatives segment is expected to grow at the fastest CAGR of approximately 13% during the forecast period.
• By distribution channel type, the government public health supplies segment held an approximate 60% share in the market in 2025.
• By distribution channel type, the international aid/donor supply chains segment is expected to grow at the fastest CAGR of approximately 14% during the forecast period.
• By end user, the public healthcare facilities segment held an approximate 62% share in the market in 2025.
• By end user, the community health centers segment is expected to grow at the fastest CAGR of approximately 13% during the forecast period.

Quick Facts Table

What are the Rotavirus Vaccines?

The rotavirus vaccines market is driven by increasing immunization programs and infant health awareness. The rotavirus vaccines comprise vaccines developed to prevent rotavirus infection, which is a leading cause of severe gastroenteritis in infants and young children worldwide. These vaccines are administered orally and are designed to stimulate protective immunity against rotavirus strains to reduce morbidity, mortality, and healthcare burden.

What is the Role of AI in the Rotavirus Vaccines Market?

AI plays an important role in the analysis and identification of viral gene sequences and vaccine targets, driving the development of target-specific vaccines. AI is also used to develop personalized vaccines depending on the patient's health profile, where the use of AI algorithms is promoting the development and identification of next-generation vaccine and their targets. It also helps in detecting disease outbreaks, as well as designing clinical trials.

What are the Recent Trends & Future Outlook of the Rotavirus Vaccines Market?

Growing government initiatives

Due to growing rotavirus disease outbreaks, the immunization programs conducted by the government are increasing, which is driving the adoption of stable and single-dose formulations.

Increasing Fundings

In order to enhance the accessibility and control the disease outbreaks of rotavirus, the funding from the government, WHO, UNICEF, Gavi, and private bodies is increasing, leading to new collaborations and encouraging innovations.

Blooming Innovations

The companies are focused on developing broad-spectrum rotavirus vaccines and novel platforms to enhance the safety and efficacy of the rotavirus vaccines, along with their stability.

Major Investments in the Rotavirus Vaccines Market

In March 2025, a total $1.2 million grant was awarded by GIVAX, Inc. to Indiana University Bloomington researchers, where their collaboration led to the development of a groundbreaking rotavirus-norovirus combination vaccine to combat norovirus.

Segmental Insights

By Vaccine Type Insights

Why Did the Pentavalent Rotavirus Vaccines Segment Dominate in the Rotavirus Vaccines Market in 2025?

The pentavalent rotavirus vaccines segment held the largest share of approximately 48% in the market in 2025, due to their proven effectiveness against 5 rotavirus strains. This, in turn, increased their use in various immunization programs. Moreover, their stability and affordability also increased their use.

Next-Generation/Broad-Spectrum Rotavirus Vaccines

The next-generation/broad-spectrum rotavirus vaccines segment is expected to show the highest growth with approximately 14% CAGR during the predicted time, due to enhanced effectiveness. Additionally, their longer duration of action and growing innovations are also driving their acceptance rates.

By Route of Administration Insights

How Oral Rotavirus Vaccines Segment Dominated the Rotavirus Vaccines Market in 2025?

The oral rotavirus vaccines segment led the market with approximately 95% in 2025, as they helped in enhancing gut immunity. At the same time, their non-invasive approach and ease of administration also increased their adoption rates. This, in turn, increased their adoption across the paediatric population.

Injectable (emerging formulation candidates)

The injectable (emerging formulation candidates) segment is expected to show rapid growth with approximately 16% CAGR during the predicted time, due to their rapid onset of action. They also provide an enhanced safety profile, which is increasing their use and driving the development of various combinations.

By Immunization Program Insights

Which Immunization Program Type Segment Held the Dominating Share of the Rotavirus Vaccines Market in 2025?

The government national immunization programs segment held the dominating share of approximately 70% in the market in 2025, due to mandatory vaccination schedules. This, in turn, increased the adoption of rotavirus vaccines, where the growth in funding also increased their use.

NGO/Public Health Initiatives

The NGO/public health initiatives segment is expected to show the highest growth with approximately 13% CAGR during the upcoming years, due to growing focus on high-burden regions. Moreover, the growing health awareness, rotavirus outbreaks, and emergencies are also increasing their demand.

By Distribution Channel Insights

Why the Government Public Health Supplies Segment Dominated the Rotavirus Vaccines Market?

The government public health supplies segment led the market with approximately 60% share in 2025, driven by the growth in the immunization programs. This promoted the bulk procurement of different types of rotavirus vaccines. Moreover, the support from other global agencies also encouraged their use.

International Aid/Donor Supply Chains

The international aid/donor supply chains segment is expected to show rapid growth with approximately 14% CAGR during the upcoming years, due to growing funding. This is driving the donor-funded immunization campaigns across the high-burden region to control their outbreaks, which is increasing their adoption rates.

By End User Insights

What Made Public Healthcare Facilities the Dominant Segment in the Rotavirus Vaccines Market in 2025?

The public healthcare facilities segment held the largest share of approximately 62% in the market in 2025, as they are the primary site for immunization. At the same time, the growth in the patient volume also increased their adoption rates. Furthermore, the growth of government and other health agencies' funding also increased their use.

Community Health Centers

The community health centers segment is expected to show the highest growth with approximately 13% CAGR during the upcoming years, due to growing decentralized immunization services. Moreover, the growing focus on underserved areas and preventive healthcare is also increasing their demand.

Regional Distribution

• Asia Pacific held the dominance with an approximate 35% share in the rotavirus vaccines market in 2025.
• China led the market by capturing the largest revenue share of the market in 2025. 
• MEA is expected to be the fastest-growing region with approximately 17% CAGR in the studied years.
• South Africa is anticipated to grow at a rapid CAGR during the forecast period.
• North America is expected to grow at a notable CAGR in the rotavirus vaccines market during the forecast period.
• The U.S. is anticipated to grow at a rapid CAGR during the forecast period.

Large Population Drives Asia Pacific

Asia Pacific dominated the rotavirus vaccines market with an approximate 35% share in 2025, due to the presence of a large population, which increased the incidence of rotavirus infections. At the same time, the growth in the immunization programs and government support also increased their use. Furthermore, the expanding healthcare sector also increased its manufacturing, which contributed to the market growth.

The growing paediatric population in China is increasing the demand and use of rotavirus vaccines in China. The growing incidence of rotavirus infections and government-funded immunization programs also increased their use. This is increasing rotavirus vaccine production and innovations.

Growing Rotavirus Burden Boosts MEA

MEA is expected to host the fastest-growing rotavirus vaccine market with approximately 17% CAGR during the forecast period, due to the growing rotavirus disease burden. Additionally, the growing paediatric populations and increasing government initiatives are also increasing their use. Moreover, the growing health awareness and expanding vaccination programs are also enhancing the market growth.

The demand for rotavirus vaccines across South Africa is increasing due to their high incidence rates. Moreover, the government and other health agencies are also launching new immunization programs backed by funds. Additionally, the expanding healthcare and health awareness are also increasing their use.

North America Driven by Advanced Healthcare

North America is expected to grow significantly in the rotavirus vaccines market during the forecast period, due to the presence of advanced healthcare infrastructure. The growing vaccination program and health awareness are also increasing their use. Moreover, the growing innovation of advanced vaccines is also promoting the market growth.

The U.S. consists of a robust healthcare sector, which is increasing the use of rotavirus vaccines. Similarly, the growing routine childhood immunization programs supported by the government and provincial funding are also increasing their adoption rates, where the companies are focusing on developing advanced retrovirus vaccines.

Rotavirus Vaccines Market Value Chain Analysis

R&D

• The R&D for retrovirus vaccine focuses on developing heat-stable formulations, dissolvable microarray patches, and neonatal vaccines.
• Key players: Serum Institute of India, Emory University, PT Bio Farma.

Clinical Trials and Regulatory Approvals

• Safety, immunogenicity, and prevention of severe gastroenteritis are evaluated in the clinical trials and regulatory approval of rotavirus vaccines.
• Key players: Sinovac, PT Bio Farma, Micron Biomedical.

Patient Support and Services

• Financial assistance programs and educational resources are provided in the patient support and services of the rotavirus vaccines.
• Key players: Serum Institute of India, Merck & Co., GSK.

Top Vendors in the Rotavirus Vaccines Market and Their Offerings

SWOT Analysis

Strength

• The proven effectiveness and safety of the rotavirus vaccines are increasing their adoption rates.
• The presence of both oral and injectable populations is increasing the acceptance rates of the rotavirus vaccines, enhancing their flexibility.
• The growing vaccination programs supported by government funding are also increasing access to the rotavirus vaccines.
• Moreover, the growing routine childhood vaccine schedules are also driving their demand.

Weakness

• The rural and undeveloped area lacks the proper immunization services, which reduces the use of rotavirus vaccines.
• Safety concerns and low effectiveness in the patient with enteric infection and malnutrition also decrease their adoption rates.

Opportunity

• Growing rotavirus disease awareness is increasing their diagnosis, driving the early adoption of various rotavirus vaccines.
• The growing government immunization programs are also increasing the adoption of rotavirus vaccines, which are supported by funding.
• Moreover, the companies are developing novel rotavirus vaccines to provide a longer duration of action and enhance immunity.
• Expanding health care across the underserved areas is also increasing the adoption and use of the rotavirus vaccines.

Threats

• The cost associated with the rotavirus vaccines is high, as they require specialized facilities, stringent quality control, and skilled personnel, which limits their acceptance rates.
• Additionally, complex manufacturing processes affect the potency and safety of the vaccines, limiting their innovations.

What are the Recent Developments in the Rotavirus Vaccines Market?

• In June 2025, the initiation of the enrollment of participants for the first clinical trial of CC24, which is a novel rotavirus vaccine delivered through dissolvable microarray technology, was announced by Emory University and Micron Biomedical.
• In April 2025, Phase III clinical trials for the Oral Pentavalent Rotavirus Vaccine (Vero Cell) to prevent rotavirus gastroenteritis targeting infants aged 6 weeks to 32 weeks were announced to have been initiated by BioKangtai.

Segments Covered in the Report

By Vaccine Type

• Monovalent Rotavirus Vaccines 
• Pentavalent Rotavirus Vaccines 
• Next-Generation/Broad-Spectrum Rotavirus Vaccines 

By Route of Administration

• Oral Rotavirus Vaccines 
• Injectable (emerging formulation candidates) 

By Immunization Program

• Government National Immunization Programs
• Private Healthcare Vaccination Programs
• NGO/Public Health Initiatives

By Distribution Channel

• Hospital & Clinic Pharmacies
• Government Public Health Supplies
• Retail Pharmacies/Drug Stores
• International Aid/Donor Supply Chains

By End-User

• Public Healthcare Facilities
• Private Hospitals & Clinics
• Community Health Centers
• International Health Organizations

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA